Clinical Trial Update: Pioglitazone and Insulin Resistance in ADT [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pioglitazone for insulin resistance in the context of androgen deprivation therapy for prostate cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insulin Resistance
• Prostate Cancer
• Type 2 Diabetes Mellitus

Drugs mentioned

• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: State University of New York at Buffalo | Conditions: Prostate Cancer, Insulin Resistance | Phase 3 | Status: WITHDRAWN